We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
OUI's momentum continues to build even under lockdown in a COVID-defying quarter.
New Oxford spinout Oxsed will lead commercialisation of rapid, cost-effective COVID-19 test.
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19
Welcome to the Oxford University Innovation Q1 2020 update. OUI is now a month into its status as a virtual company with the entire office working from home, but we remain very much open for business. Below you’ll find all the usual updates from OUI and news from our spinouts, as well as an update on how Oxford is responding to the ongoing crisis.
Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders.
Y Combinator startup Prolific announces $1.2M seed round with participation from Pioneer Fund and prominent Silicon Valley Angel investors.
Oxford spinout developing novel therapeutics based on deep expertise in immune cell regulation.
MoA Technology, borne out of Oxford University research, launches to confront the global herbicide resistance crisis with £6.3m Series A funding round.
The Oxford University spinout company launches to look inside the brain for novel markers of disease.
LAB10x launched and AI@Oxford on the horizon in another active quarter for the Oxford Innovation Ecosystem.
